Medication info
Glycomin Extended-Release Tablet 500 mg (Metformin Hydrochloride)

Glycomin Extended-Release Tablet 500 mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Ilsung IS Co., Ltd.
Appearance
White to yellowish oblong tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201402049 · Approved 2014.04.30 · Insurance code 655403260

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on efficacy and tolerability, and should not exceed the recommended maximum daily dose. The usual starting dose is one extended-release metformin hydrochloride 500mg tablet once daily with the evening meal. Blood glucose levels should be measured after one week to adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. For patients already receiving metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to this medicine and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. The goal of treatment with this medicine, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Ilsung IS Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used to effectively manage blood sugar levels in adult patients with type 2 diabetes who have difficulty controlling their blood sugar with diet and exercise alone, particularly those who are overweight. It helps in blood sugar control and contributes to the prevention of complications when used alone or in combination with other oral hypoglycemic agents or insulin. It is a safe and effective treatment method that can be adjusted according to the patient's condition.

How to take

Adult dose

The dose should be determined individually based on efficacy and tolerability, and should not exceed the recommended maximum daily dose. The usual starting dose is one extended-release metformin hydrochloride 500mg tablet once daily with the evening meal. Blood glucose levels should be measured after one week to adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. For patients already receiving metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to this medicine and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. The goal of treatment with this medicine, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Precautions

This medication can rarely cause a serious metabolic complication called lactic acidosis, which has been reported to lead to death. Caution is necessary if used with other diabetes medications, as severe hypoglycemia may occur. It should not be administered to patients with moderate to severe renal impairment, dehydration, severe infections, acute myocardial infarction, or other acute conditions that can affect renal function. Patients with acute or unstable heart failure should also avoid using this medication. Administration should be discontinued before and after the use of iodine contrast agents, and reinstituted only after confirming normal renal function. It should not be given to patients who have had an allergic reaction to any component of this medication, patients with type 1 diabetes, or patients experiencing diabetic ketoacidosis. During severe infections, major trauma, or surgical procedures, it is advisable to temporarily discontinue this medication and restart it once the patient's condition has stabilized. Patients with poor nutritional status, liver dysfunction, respiratory failure, or excessive alcohol intake also require caution when using this medication. This medication is primarily excreted by the kidneys, so renal function should be monitored regularly, and administration should be stopped immediately if there is a sudden decline in renal function. Additionally, the use of this medication may result in vitamin B12 deficiency, so serum vitamin B12 levels should be checked regularly. Gastrointestinal adverse effects are common during the initial treatment but usually improve over time. Excessive acute or chronic alcohol intake should be avoided during the use of this medication, and caution is required when used in combination with other medications that pose a risk of hypoglycemia. During pregnancy, this medication may affect fetal growth, so pregnant women should consult a doctor before taking it and exercise caution while breastfeeding. Elderly patients commonly experience reduced renal function, so dose adjustment and regular monitoring of renal function are necessary. In cases of overdose, there is a risk of lactic acidosis rather than hypoglycemia, and treatment should be sought immediately from a medical institution, where blood dialysis may be beneficial. This medication should not be chewed or crushed but swallowed whole, and it is normal for the tablet coating to be expelled in the stool. Finally, it is important to conduct regular blood sugar and renal function tests during the use of this medication to continuously monitor treatment effectiveness and safety.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • itching
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly closed container. Furthermore, it is important to keep it at a cool temperature below 25 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

White to yellowish oblong tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.